Artivion, Inc. logo

Artivion, Inc.

AORT

NYSEHealthcareMedical - Devices

Previous close

$28.08

+$0.10 · +0.36%

Aug 21, 4:00 PM ET

AORT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

60

Fair Value

Momentum

26

Weakening

Sentiment

72

Bullish

Risk resilience

36

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
James Patrick Mackin
Listed since
Feb 12, 1993
Employees
1,800

Market position

Day range

Current $28.08

52-week range

Current $28.08

Open
$27.98
Previous close
$27.98
Volume
383.35K
0.52× average
Average volume
734.54K
Average daily volume
Market cap
1.36B USD
Beta
1.25
Market reference 1
50-day average
$24.9674
+12.47% above average
200-day average
$34.7026
-19.08% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.29B USD
P/E (TTM)
-471.14×
P/B (TTM)
3.06×
P/S (TTM)
2.89×
EV / EBITDA
35.96×
Earnings yield
0.47%
Free cash flow yield
-0.04%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
62.80%
Operating margin
4.00%
Net margin
-0.67%
Return on equity
2.18%
Return on assets
1.10%
Return on invested capital
2.24%

Financial health

Debt / equity
0.92×
Current ratio
2.99×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends74%44%14%-16%Gross margin, FY2021: 66.09%Gross margin, FY2022: 64.54%Gross margin, FY2023: 64.74%Gross margin, FY2024: 64.03%Gross margin, FY2025: 61.28%Operating margin, FY2021: 2.72%Operating margin, FY2022: 1.98%Operating margin, FY2023: 1.62%Operating margin, FY2024: 10.01%Operating margin, FY2025: 6.06%Net margin, FY2021: -4.96%Net margin, FY2022: -6.12%Net margin, FY2023: -8.67%Net margin, FY2024: -3.44%Net margin, FY2025: 2.21%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 66.09%. Gross margin FY2022 64.54%. Gross margin FY2023 64.74%. Gross margin FY2024 64.03%. Gross margin FY2025 61.28%. Operating margin FY2021 2.72%. Operating margin FY2022 1.98%. Operating margin FY2023 1.62%. Operating margin FY2024 10.01%. Operating margin FY2025 6.06%. Net margin FY2021 -4.96%. Net margin FY2022 -6.12%. Net margin FY2023 -8.67%. Net margin FY2024 -3.44%. Net margin FY2025 2.21%.

Income trends

Revenue

441.33M USD+13.59%

Operating income

26.75M USD-31.20%

Net income

9.77M USD+23.13M USD
Income trends across reported periods488.53M USD299.72M USD110.92M USD−77.89M USDRevenue, FY2021: 298.84M USDRevenue, FY2022: 313.79M USDRevenue, FY2023: 354M USDRevenue, FY2024: 388.54M USDRevenue, FY2025: 441.33M USDOperating income, FY2021: 8.12M USDOperating income, FY2022: 6.2M USDOperating income, FY2023: 5.74M USDOperating income, FY2024: 38.87M USDOperating income, FY2025: 26.75M USDNet income, FY2021: −14.83M USDNet income, FY2022: −19.19M USDNet income, FY2023: −30.69M USDNet income, FY2024: −13.36M USDNet income, FY2025: 9.77M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 298.84M USD. Revenue FY2022 313.79M USD. Revenue FY2023 354M USD. Revenue FY2024 388.54M USD. Revenue FY2025 441.33M USD. Operating income FY2021 8.12M USD. Operating income FY2022 6.2M USD. Operating income FY2023 5.74M USD. Operating income FY2024 38.87M USD. Operating income FY2025 26.75M USD. Net income FY2021 −14.83M USD. Net income FY2022 −19.19M USD. Net income FY2023 −30.69M USD. Net income FY2024 −13.36M USD. Net income FY2025 9.77M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue441.33M USD388.54M USD354M USD313.79M USD298.84M USD
Cost of goods sold170.88M USD139.76M USD124.83M USD111.27M USD101.32M USD
Gross profit270.45M USD248.78M USD229.18M USD202.52M USD197.51M USD
Research and development30.99M USD28.45M USD28.71M USD38.88M USD35.55M USD
Selling, general, and administrative212.72M USD192.38M USD208.98M USD157.44M USD169.77M USD
Operating expenses243.71M USD209.91M USD223.43M USD196.32M USD189.4M USD
Interest income763K USD1.47M USD1.08M USD147K USD79K USD
Interest expense26.58M USD34.28M USD25.3M USD18.22M USD16.89M USD
Depreciation and amortization22.46M USD24.21M USD23.08M USD22.44M USD23.98M USD
Operating income26.75M USD38.87M USD5.74M USD6.2M USD8.12M USD
Net income9.77M USD−13.36M USD−30.69M USD−19.19M USD−14.83M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
27%
3 beats, 8 misses, 0 met estimates
Average EPS surprise
-1429.42%
11 comparable reports
Latest EPS result
-0.28
Estimate 0 · Miss by 11300.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.2-0.01-0.22-0.43Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 24, 2025: actual -0.39, estimate -0.01, surprise -3800.00%, Miss. Q2 2025, reported May 5, 2025: actual -0.01, estimate 0.12, surprise -108.33%, Miss. Q3 2025, reported Aug 7, 2025: actual 0.03, estimate 0.11, surprise -72.45%, Miss. Q4 2025, reported Nov 6, 2025: actual 0.16, estimate 0.14, surprise +14.29%, Beat. Q1 2026, reported Feb 12, 2026: actual 0.051, estimate 0.14, surprise -63.57%, Miss. Q2 2026, reported May 7, 2026: actual 0.03, estimate 0.06, surprise -50.00%, Miss. Q3 2026, reported Aug 6, 2026: actual -0.28, estimate 0.003, surprise -11300.00%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate 0.11, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates130.79M117.12M103.46M89.79MQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 24, 2025: actual 97.31M USD, estimate 100.89M USD, surprise -3.55%, Miss. Q2 2025, reported May 5, 2025: actual 98.98M USD, estimate 94.82M USD, surprise +4.38%, Beat. Q3 2025, reported Aug 7, 2025: actual 112.97M USD, estimate 108.03M USD, surprise +4.57%, Beat. Q4 2025, reported Nov 6, 2025: actual 113.39M USD, estimate 110.44M USD, surprise +2.67%, Beat. Q1 2026, reported Feb 12, 2026: actual 115.99M USD, estimate 116.47M USD, surprise -0.41%, Miss. Q2 2026, reported May 7, 2026: actual 116.34M USD, estimate 115.69M USD, surprise +0.56%, Beat. Q3 2026, reported Aug 6, 2026: actual 125.76M USD, estimate 119.99M USD, surprise +4.80%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 120.93M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$42.50

51.35% upside
Past 12 months12-month forecastHigh $45.00Average $42.50Low $40.00

Rating distribution

12 ratings
Strong buy00%
Buy1083%
Hold217%
Sell00%
Strong sell00%

Recent analyst actions

9 institutions
Citizens Capital MarketsmaintainMarket Outperform

AORT peers

ETFs holding AORT

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research AORT

research.disclaimer